|
US7407943B2
(en)
*
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
|
US20060009410A1
(en)
*
|
2002-11-13 |
2006-01-12 |
Crooke Rosanne M |
Effects of apolipoprotein B inhibition on gene expression profiles in animals
|
|
US7511131B2
(en)
|
2002-11-13 |
2009-03-31 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
|
JP2005244488A
(ja)
|
2004-02-25 |
2005-09-08 |
Matsushita Electric Ind Co Ltd |
複合機
|
|
US20050287558A1
(en)
|
2004-05-05 |
2005-12-29 |
Crooke Rosanne M |
SNPs of apolipoprotein B and modulation of their expression
|
|
EP2388326A1
(en)
*
|
2005-09-19 |
2011-11-23 |
Isis Pharmaceuticals, Inc. |
Modulation of glucagon receptor expression
|
|
CN103301475B
(zh)
|
2005-12-28 |
2016-08-03 |
斯克里普斯研究所 |
药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用
|
|
US7764650B2
(en)
|
2006-03-02 |
2010-07-27 |
Intel Corporation |
Mobile station and method for fast roaming with integrity protection and source authentication using a common protocol
|
|
EA201100813A1
(ru)
|
2006-04-03 |
2012-06-29 |
Сантарис Фарма А/С |
Фармацевтическая композиция
|
|
US20100004320A1
(en)
|
2006-04-03 |
2010-01-07 |
Santaris Pharma A/S |
Pharmaceutical Composition
|
|
EP2015758B1
(en)
|
2006-05-05 |
2014-04-02 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression apob
|
|
CA2658183A1
(en)
*
|
2006-07-17 |
2008-01-24 |
Sirna Therapeutics Inc. |
Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina)
|
|
ES2620472T5
(es)
*
|
2006-10-18 |
2020-07-09 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido
|
|
US8093222B2
(en)
*
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
|
US8084437B2
(en)
|
2006-11-27 |
2011-12-27 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
|
EP2126079A1
(en)
*
|
2007-03-22 |
2009-12-02 |
Santaris Pharma A/S |
Rna antagonist compounds for the inhibition of apo-b100 expression
|
|
CA2682082A1
(en)
*
|
2007-03-24 |
2008-10-02 |
Genzyme Corporation |
Administering antisense oligonucleotides complementary to human apolipoprotein b
|
|
JP2010524486A
(ja)
|
2007-05-01 |
2010-07-22 |
サンタリス ファーマ アー／エス |
β−カテニンを調節するためのＲＮＡアンタゴニスト化合物
|
|
BRPI0811156A2
(pt)
|
2007-05-11 |
2019-09-24 |
Enzon Pharmaceuticals Inc |
compostos antagonistas de rna para a modulação de her3
|
|
WO2009006478A2
(en)
†
|
2007-07-05 |
2009-01-08 |
Isis Pharmaceuticals, Inc. |
6-disubstituted bicyclic nucleic acid analogs
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
WO2009046426A2
(en)
*
|
2007-10-04 |
2009-04-09 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for improving cellular uptake of oligomeric compounds
|
|
EA019939B1
(ru)
|
2007-10-04 |
2014-07-30 |
Сантарис Фарма А/С |
МОДИФИЦИРОВАННЫЙ ОЛИГОМЕР ДЛЯ УМЕНЬШЕНИЯ КОЛИЧЕСТВА микроРНК В КЛЕТКЕ
|
|
NZ585327A
(en)
|
2007-11-26 |
2012-10-26 |
Santaris Pharma As |
Lna antagonists targeting the androgen receptor
|
|
US8450290B2
(en)
|
2007-11-26 |
2013-05-28 |
Enzon Pharmaceuticals, Inc. |
Methods for treating androgen receptor dependent disorders including cancers
|
|
JP2011505798A
(ja)
*
|
2007-12-07 |
2011-03-03 |
サンタリス ファーマ アー／エス |
Ｍｃｌ−１を調節するためのＲＮＡアンタゴニスト化合物
|
|
AU2009213147A1
(en)
|
2008-02-11 |
2009-08-20 |
Rxi Pharmaceuticals Corp. |
Modified RNAi polynucleotides and uses thereof
|
|
US8361980B2
(en)
|
2008-03-07 |
2013-01-29 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microRNA related diseases
|
|
US8426378B2
(en)
|
2008-03-21 |
2013-04-23 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucelosides and methods for their use
|
|
EP2274423A2
(en)
*
|
2008-04-04 |
2011-01-19 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
|
WO2009127680A1
(en)
*
|
2008-04-16 |
2009-10-22 |
Santaris Pharma A/S |
Pharmaceutical composition comprising anti pcsk9 oligomers
|
|
WO2009143390A2
(en)
|
2008-05-22 |
2009-11-26 |
Isis Pharmaceuticals, Inc. |
Methods for modulating expression of rbp4
|
|
WO2009148605A2
(en)
*
|
2008-06-04 |
2009-12-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
|
EP2297322A1
(en)
|
2008-06-04 |
2011-03-23 |
The Board of Regents of The University of Texas System |
Modulation of gene expression through endogenous small rna targeting of gene promoters
|
|
AU2009276763B2
(en)
|
2008-07-29 |
2015-07-16 |
The Board Of Regents Of The University Of Texas Sytem |
Selective inhibition of polyglutamine protein expression
|
|
WO2010012667A1
(en)
|
2008-08-01 |
2010-02-04 |
Santaris Pharma A/S |
Micro-rna mediated modulation of colony stimulating factors
|
|
GB2465902B
(en)
|
2008-08-25 |
2010-12-08 |
Excaliard Pharmaceuticals Inc |
Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
|
|
ES2657696T3
(es)
|
2008-08-25 |
2018-03-06 |
Excaliard Pharmaceuticals, Inc. |
Método para reducir la cicatrización durante la curación de una herida utilizando compuestos antisentido dirigidos al CTGF
|
|
JP2012502991A
(ja)
|
2008-09-22 |
2012-02-02 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
皮膚適用におけるｒｎａ干渉
|
|
CA2739464C
(en)
|
2008-10-03 |
2020-03-31 |
Opko Curna, Llc |
Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
|
|
DK2379084T3
(en)
*
|
2008-10-15 |
2018-01-22 |
Ionis Pharmaceuticals Inc |
MODULATION OF FACTOR 11 EXPRESSION
|
|
CA2741294C
(en)
*
|
2008-10-24 |
2018-04-24 |
Isis Pharmaceuticals, Inc. |
5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
|
|
AU2009323766B2
(en)
|
2008-12-02 |
2016-10-06 |
Wave Life Sciences Ltd. |
Method for the synthesis of phosphorus atom modified nucleic acids
|
|
KR101829469B1
(ko)
|
2008-12-04 |
2018-03-30 |
큐알엔에이, 인크. |
Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
|
|
EP2370581B1
(en)
|
2008-12-04 |
2016-08-03 |
CuRNA, Inc. |
Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
|
|
WO2010065787A2
(en)
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
|
SG173182A1
(en)
*
|
2009-02-03 |
2011-09-29 |
Hoffmann La Roche |
Compositions and methods for inhibiting expression of ptp1b genes
|
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
|
CN102439149B
(zh)
*
|
2009-02-12 |
2018-01-02 |
库尔纳公司 |
通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
|
|
WO2010093904A2
(en)
|
2009-02-12 |
2010-08-19 |
Curna, Inc. |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
|
EP2408919B1
(en)
|
2009-03-16 |
2017-10-18 |
CuRNA, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
|
US9107933B2
(en)
|
2009-03-16 |
2015-08-18 |
Isis Pharmaceuticals, Inc. |
Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III
|
|
EP2408920B1
(en)
|
2009-03-17 |
2017-03-08 |
CuRNA, Inc. |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
|
EP2421972A2
(en)
|
2009-04-24 |
2012-02-29 |
The Board of Regents of The University of Texas System |
Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
|
|
ES2599979T3
(es)
|
2009-04-24 |
2017-02-06 |
Roche Innovation Center Copenhagen A/S |
Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
|
|
KR101835889B1
(ko)
|
2009-05-06 |
2018-03-08 |
큐알엔에이, 인크. |
지질 수송 및 대사 유전자에 대한 천연 안티센스 전사체의 억제에 의해 지질 수송 및 대사 유전자 관련된 질환의 치료
|
|
CN102803492B
(zh)
|
2009-05-06 |
2016-06-29 |
库尔纳公司 |
通过抑制针对三重四脯氨酸(ttp)的天然反义转录物来治疗ttp相关疾病
|
|
CN102459597B
(zh)
|
2009-05-08 |
2020-06-30 |
库尔纳公司 |
通过针对dmd家族的天然反义转录物的抑制治疗肌营养蛋白家族相关疾病
|
|
TW201102091A
(en)
*
|
2009-05-15 |
2011-01-16 |
Hoffmann La Roche |
Compositions and methods for inhibiting expression of glucocorticoid receptor (GCR) genes
|
|
CN102575251B
(zh)
|
2009-05-18 |
2018-12-04 |
库尔纳公司 |
通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病
|
|
US8895527B2
(en)
|
2009-05-22 |
2014-11-25 |
Curna, Inc. |
Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3
|
|
CA2764683A1
(en)
|
2009-05-28 |
2010-12-02 |
Joseph Collard |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
|
JP5944311B2
(ja)
|
2009-06-16 |
2016-07-05 |
クルナ・インコーポレーテッド |
コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
|
|
WO2010148065A2
(en)
|
2009-06-16 |
2010-12-23 |
Curna, Inc. |
Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
|
|
WO2010151671A2
(en)
|
2009-06-24 |
2010-12-29 |
Curna, Inc. |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
|
KR101807324B1
(ko)
|
2009-06-26 |
2017-12-08 |
큐알엔에이, 인크. |
다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료
|
|
SG177564A1
(en)
|
2009-07-06 |
2012-02-28 |
Ontorii Inc |
Novel nucleic acid prodrugs and methods of use thereof
|
|
EP2456870A1
(en)
|
2009-07-21 |
2012-05-30 |
Santaris Pharma A/S |
Antisense oligomers targeting pcsk9
|
|
KR101801407B1
(ko)
|
2009-07-24 |
2017-11-24 |
큐알엔에이, 인크. |
시르투인 (ｓｉｒｔ)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료
|
|
KR101802536B1
(ko)
|
2009-08-05 |
2017-11-28 |
큐알엔에이, 인크. |
인슐린 유전자 (ｉｎｓ)에 대한 자연 안티센스 전사체의 저해에 의한 인슐린 유전자 (ｉｎｓ) 관련된 질환의 치료
|
|
EP2464731B1
(en)
|
2009-08-11 |
2016-10-05 |
CuRNA, Inc. |
Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
|
|
WO2011022606A2
(en)
|
2009-08-21 |
2011-02-24 |
Curna, Inc. |
Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
|
|
WO2011031482A2
(en)
|
2009-08-25 |
2011-03-17 |
Curna, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
|
EP2480667A4
(en)
*
|
2009-09-25 |
2013-07-03 |
Isis Pharmaceuticals Inc |
MODULATION OF TTC39 EXPRESSION FOR HDL INCREASE
|
|
WO2011038210A2
(en)
|
2009-09-25 |
2011-03-31 |
Curna, Inc. |
Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
|
|
DK3252068T3
(da)
|
2009-10-12 |
2025-08-25 |
Larry J Smith |
Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro
|
|
JP5859970B2
(ja)
*
|
2009-10-12 |
2016-02-16 |
メディミューン，エルエルシー |
腫瘍分類のためのｉｒ−ａ及びｉｒ−ｂの定量
|
|
WO2011053994A1
(en)
|
2009-11-02 |
2011-05-05 |
Alnylam Pharmaceuticals, Inc. |
Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
|
|
WO2011054811A1
(en)
|
2009-11-03 |
2011-05-12 |
Santaris Pharma A/S |
Rna antagonists targeting hsp27 combination therapy
|
|
CA2782366A1
(en)
|
2009-12-16 |
2011-07-14 |
Opko Curna, Llc |
Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
|
|
US9068183B2
(en)
|
2009-12-23 |
2015-06-30 |
Curna, Inc. |
Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
|
|
KR101891352B1
(ko)
|
2009-12-23 |
2018-08-24 |
큐알엔에이, 인크. |
간세포 성장 인자(ｈｇｆ)에 대한 천연 안티센스 전사체의 억제에 의한 ｈｇｆ 관련 질환의 치료
|
|
WO2011090741A2
(en)
|
2009-12-29 |
2011-07-28 |
Opko Curna, Llc |
TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
|
|
CA2785173A1
(en)
|
2009-12-29 |
2011-07-28 |
Curna, Inc. |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
|
RU2016115782A
(ru)
|
2009-12-31 |
2018-11-28 |
Курна, Инк. |
Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2 и транскрипционному фактору е3 (tfe3)
|
|
CN102906264B
(zh)
|
2010-01-04 |
2017-08-04 |
库尔纳公司 |
通过抑制干扰素调节因子8(irf8)的天然反义转录物而治疗irf8相关疾病
|
|
RU2612161C2
(ru)
|
2010-01-06 |
2017-03-02 |
Курна, Инк. |
Лечение заболеваний, связанных с геном развития поджелудочной железы, путем ингибирования природного антисмыслового транскрипта к гену развития поджелудочной железы
|
|
WO2011085271A2
(en)
|
2010-01-08 |
2011-07-14 |
Isis Pharmaceuticals, Inc. |
Modulation of angiopoietin-like 3 expression
|
|
ES2664866T3
(es)
|
2010-01-11 |
2018-04-23 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg
|
|
WO2011088148A1
(en)
*
|
2010-01-12 |
2011-07-21 |
Isis Pharmaceuticals, Inc. |
Modulation of transforming growth factor-beta 1 expression
|
|
KR101853510B1
(ko)
|
2010-01-25 |
2018-06-20 |
큐알엔에이, 인크. |
Ｒｎａｓｅ ｈ1에 대한 천연 안티센스 전사체의 억제에 의한 ｒｎａｓｅ ｈ1과 관련된 질환의 치료
|
|
WO2011097388A1
(en)
|
2010-02-03 |
2011-08-11 |
Alnylam Pharmaceuticals, Inc. |
Selective inhibition of polyglutamine protein expression
|
|
EP3321361B1
(en)
|
2010-02-08 |
2019-03-27 |
Ionis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
|
WO2011097644A2
(en)
*
|
2010-02-08 |
2011-08-11 |
Isis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
|
US8962586B2
(en)
|
2010-02-22 |
2015-02-24 |
Curna, Inc. |
Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US9068185B2
(en)
*
|
2010-03-12 |
2015-06-30 |
Sarepta Therapeutics, Inc. |
Antisense modulation of nuclear hormone receptors
|
|
EP2550002B1
(en)
|
2010-03-24 |
2019-05-08 |
Phio Pharmaceuticals Corp. |
Rna interference in dermal and fibrotic indications
|
|
RU2612884C2
(ru)
|
2010-04-02 |
2017-03-13 |
Курна, Инк. |
Лечение заболеваний, связанных с колониестимулирующим фактором 3 (csf3), путем ингибирования природного антисмыслового транскрипта k csf3
|
|
EP3517613A1
(en)
|
2010-04-09 |
2019-07-31 |
CuRNA, Inc. |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
|
WO2011139387A1
(en)
*
|
2010-05-03 |
2011-11-10 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
|
TWI586356B
(zh)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
|
|
EP2576783B1
(en)
|
2010-05-26 |
2017-11-29 |
CuRNA, Inc. |
Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
|
|
CA2799596C
(en)
|
2010-05-26 |
2020-09-22 |
Curna, Inc. |
Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
|
|
JP6109069B2
(ja)
|
2010-06-04 |
2017-04-05 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
ｍｉＲ−３７８による代謝調節
|
|
WO2011156763A1
(en)
*
|
2010-06-11 |
2011-12-15 |
Hitachi Chemical Co., Ltd. |
Methods for characterizing kidney function
|
|
WO2011156734A2
(en)
|
2010-06-11 |
2011-12-15 |
Hitachi Chemical Co., Ltd. |
Method of characterizing vascular diseases
|
|
US9518259B2
(en)
|
2010-06-15 |
2016-12-13 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating interaction between proteins and target nucleic acids
|
|
US8933024B2
(en)
|
2010-06-18 |
2015-01-13 |
Sanofi |
Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
PL2585596T3
(pl)
|
2010-06-23 |
2021-06-28 |
Curna, Inc. |
Leczenie chorób związanych z podjednostką alfa kanału sodowego bramkowanego napięciem (SCNA) poprzez hamowanie naturalnego transkryptu antysensownego SCNA
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
JP5998131B2
(ja)
|
2010-07-14 |
2016-09-28 |
カッパーアールエヌエー，インコーポレイテッド |
Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療
|
|
WO2012029870A1
(ja)
*
|
2010-08-31 |
2012-03-08 |
国立大学法人大阪大学 |
オリゴヌクレオチド、およびオリゴヌクレオチドを有効成分として含有する脂質異常症治療剤
|
|
WO2012034942A1
(en)
|
2010-09-13 |
2012-03-22 |
Santaris Pharma A/S |
Compounds for the modulation of aurora kinase b expression
|
|
EP2620428B1
(en)
|
2010-09-24 |
2019-05-22 |
Wave Life Sciences Ltd. |
Asymmetric auxiliary group
|
|
WO2012047956A2
(en)
|
2010-10-06 |
2012-04-12 |
Opko Curna Llc |
Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
|
|
WO2012054723A2
(en)
|
2010-10-22 |
2012-04-26 |
Opko Curna Llc |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
|
DK2638163T3
(en)
|
2010-11-12 |
2017-07-24 |
Massachusetts Gen Hospital |
POLYCOMB-ASSOCIATED NON-CODING RNAs
|
|
US10000752B2
(en)
|
2010-11-18 |
2018-06-19 |
Curna, Inc. |
Antagonat compositions and methods of use
|
|
WO2012066093A1
(en)
|
2010-11-19 |
2012-05-24 |
Santaris Pharma A/S |
Compounds for the modulation of pdz-binding kinase (pbk) expression
|
|
WO2012066092A1
(en)
|
2010-11-19 |
2012-05-24 |
Santaris Pharma A/S |
Compounds for the modulation of aurora kinase a expression
|
|
KR102010598B1
(ko)
|
2010-11-23 |
2019-08-13 |
큐알엔에이, 인크. |
Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
|
|
JO3756B1
(ar)
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
|
US8771696B2
(en)
|
2010-11-23 |
2014-07-08 |
Regeneron Pharmaceuticals, Inc. |
Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
|
|
AR084938A1
(es)
|
2011-01-28 |
2013-07-10 |
Sanofi Sa |
Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes
|
|
ES2729956T3
(es)
|
2011-02-02 |
2019-11-07 |
Excaliard Pharmaceuticals Inc |
Compuestos antisentido dirigidos al factor de crecimiento de tejido conectivo (ctgf) para su uso en un procedimiento de tratamiento de queloides o cicatrices hipertróficas
|
|
US10017764B2
(en)
|
2011-02-08 |
2018-07-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
WO2012110457A2
(en)
|
2011-02-14 |
2012-08-23 |
Santaris Pharma A/S |
Compounds for the modulation of osteopontin expression
|
|
AU2012242642A1
(en)
|
2011-04-13 |
2013-05-02 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
|
WO2012143427A1
(en)
|
2011-04-19 |
2012-10-26 |
Santaris Pharma A/S |
Anti polyomavirus compounds
|
|
EP2699271A4
(en)
|
2011-04-20 |
2015-10-07 |
Larry J Smith |
METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING COMPONENTS THAT SELF-ASSEMBLED IN CELLS AND PRODUCE RNAI ACTIVITY
|
|
WO2012170771A1
(en)
|
2011-06-09 |
2012-12-13 |
Curna, Inc. |
Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
|
|
JP5823031B2
(ja)
|
2011-06-10 |
2015-11-25 |
日立化成株式会社 |
小胞捕捉デバイスおよびそれを用いるための方法
|
|
US9605019B2
(en)
|
2011-07-19 |
2017-03-28 |
Wave Life Sciences Ltd. |
Methods for the synthesis of functionalized nucleic acids
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
DK2742135T4
(da)
|
2011-08-11 |
2020-07-13 |
Ionis Pharmaceuticals Inc |
Bindingsmodificerede gapped oligomeriske forbindelser og anvendelser deraf
|
|
WO2013036403A1
(en)
|
2011-09-06 |
2013-03-14 |
Curna, Inc. |
TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
US9580708B2
(en)
|
2011-09-14 |
2017-02-28 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotides compounds
|
|
ES2773111T3
(es)
|
2011-09-16 |
2020-07-09 |
Regeneron Pharma |
Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
|
|
CA2849273C
(en)
|
2011-09-20 |
2020-07-21 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of gcgr expression
|
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
RU2014119787A
(ru)
|
2011-10-25 |
2015-12-10 |
Айсис Фармасьютикалс, Инк. |
Антисмысловая регуляция экспрессии gccr
|
|
CN104126010B
(zh)
|
2011-12-16 |
2021-04-06 |
国立大学法人东京医科齿科大学 |
嵌合的双链核酸
|
|
DK2825648T3
(en)
|
2012-03-15 |
2018-10-15 |
Curna Inc |
TREATMENT OF BRAIN-DERIVATIVE NEUROTROPHIC FACTOR (BDNF) -related DISEASES BY INHIBITATION OF NATURAL ANTISENCE TRANSCRIPTION TO BDNF
|
|
EP2831232A4
(en)
*
|
2012-03-30 |
2015-11-04 |
Univ Washington |
METHODS OF MODULATING THE EXPRESSION OF TAU TO REDUCE THE STROKE AND MODIFY A NEURODEGENERATIVE SYMPTOM
|
|
WO2013159108A2
(en)
*
|
2012-04-20 |
2013-10-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
EP2850185A4
(en)
|
2012-05-16 |
2015-12-30 |
Rana Therapeutics Inc |
COMPOSITIONS AND METHOD FOR MODULATING UTRN GENE EXPRESSION
|
|
WO2013173652A1
(en)
*
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating gene expression
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
CA2873779A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating mecp2 expression
|
|
KR20150030205A
(ko)
|
2012-05-16 |
2015-03-19 |
라나 테라퓨틱스, 인크. |
Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법
|
|
EA201492118A1
(ru)
*
|
2012-05-16 |
2015-04-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии pten
|
|
CN104583401A
(zh)
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
用于调节atp2a2表达的组合物和方法
|
|
BR112014028631A2
(pt)
|
2012-05-16 |
2017-10-17 |
Rana Therapeutics Inc |
composições e métodos para modulação da expressão da família de genes da hemoglobina
|
|
US20160002624A1
(en)
|
2012-05-17 |
2016-01-07 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
|
NZ631071A
(en)
*
|
2012-05-24 |
2017-02-24 |
Ionis Pharmaceuticals Inc |
Methods and compositions for modulating apolipoprotein(a) expression
|
|
EP2857513A4
(en)
*
|
2012-05-26 |
2016-05-25 |
Bonac Corp |
Single-stranded nucleic acid molecule controlling the expression of a gene transporter
|
|
SG10201912895PA
(en)
|
2012-07-13 |
2020-02-27 |
Wave Life Sciences Ltd |
Chiral control
|
|
JP6268157B2
(ja)
|
2012-07-13 |
2018-01-24 |
株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ |
不斉補助基
|
|
JP6246121B2
(ja)
|
2012-07-13 |
2017-12-13 |
株式会社新日本科学 |
キラル核酸アジュバント
|
|
EP2895200B1
(en)
|
2012-09-14 |
2019-11-06 |
Translate Bio MA, Inc. |
Multimeric oligonucleotide compounds
|
|
US9993522B2
(en)
|
2012-09-18 |
2018-06-12 |
Uti Limited Partnership |
Treatment of pain by inhibition of USP5 de-ubiquitinase
|
|
US9695418B2
(en)
|
2012-10-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
|
EP2906255B1
(en)
|
2012-10-12 |
2023-02-22 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
|
EP2906697A4
(en)
|
2012-10-15 |
2016-06-22 |
Ionis Pharmaceuticals Inc |
METHOD FOR MONITORING THE C9ORF72 EXPRESSION
|
|
WO2014062691A2
(en)
|
2012-10-15 |
2014-04-24 |
Isis Pharmaceuticals, Inc. |
Compositions for modulating c9orf72 expression
|
|
ES2724853T3
(es)
*
|
2012-11-15 |
2019-09-16 |
Roche Innovation Ct Copenhagen As |
Conjugados de oligonucleótidos
|
|
BR112015012051A2
(pt)
|
2012-11-26 |
2017-12-12 |
Roche Innovation Ct Copenhagen As |
composições e métodos para modulação de expressão de fgfr3
|
|
MY177989A
(en)
|
2013-01-30 |
2020-09-28 |
Hoffmann La Roche |
Lna oligonucleotide carbohydrate conjugates
|
|
US9701708B2
(en)
*
|
2013-01-31 |
2017-07-11 |
Ionis Pharmaceuticals, Inc. |
Method of preparing oligomeric compounds using modified coupling protocols
|
|
EP2961853B1
(en)
|
2013-02-28 |
2018-09-19 |
The Board of Regents of The University of Texas System |
Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
|
|
JP6440170B2
(ja)
*
|
2013-03-01 |
2018-12-19 |
国立大学法人 東京医科歯科大学 |
キメラ一本鎖アンチセンスポリヌクレオチドおよび二本鎖アンチセンス剤
|
|
KR20150130430A
(ko)
|
2013-03-14 |
2015-11-23 |
아이시스 파마수티컬즈 인코포레이티드 |
타우 발현을 조절하는 조성물 및 방법
|
|
MX359337B
(es)
|
2013-03-14 |
2018-07-09 |
Andes Biotechnologies Global Inc |
Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.
|
|
WO2014145356A1
(en)
|
2013-03-15 |
2014-09-18 |
MiRagen Therapeutics, Inc. |
Bridged bicyclic nucleosides
|
|
MX2015014666A
(es)
|
2013-04-17 |
2016-03-01 |
Pfizer |
Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
|
|
KR102138781B1
(ko)
*
|
2013-05-01 |
2020-07-28 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포지질단백질 c-iii 발현을 조절하는 조성물 및 방법
|
|
WO2014182330A1
(en)
|
2013-05-06 |
2014-11-13 |
Hitachi Chemical Company Ltd |
Devices and methods for capturing target molecules
|
|
HK1213595A1
(zh)
|
2013-05-24 |
2016-07-08 |
罗氏创新中心哥本哈根有限公司 |
B-细胞cll/淋巴瘤11a(bcl11a)的寡核苷酸调节剂及其用途
|
|
EP3004347B1
(en)
|
2013-05-30 |
2018-09-26 |
National University Corporation Tokyo Medical and Dental University |
Double-stranded agents for delivering therapeutic oligonucleotides
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
TW201534324A
(zh)
|
2013-06-07 |
2015-09-16 |
Sanofi Sa |
藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
|
|
AU2014282666A1
(en)
|
2013-06-16 |
2016-01-07 |
National University Corporation Tokyo Medical And Dental University |
Double-stranded antisense nucleic acid with exon-skipping effect
|
|
SG10201908122XA
(en)
|
2013-06-27 |
2019-10-30 |
Roche Innovation Ct Copenhagen As |
Antisense oligomers and conjugates targeting pcsk9
|
|
TWI772856B
(zh)
|
2013-07-19 |
2022-08-01 |
美商百健Ｍａ公司 |
用於調節τ蛋白表現之組合物
|
|
WO2015023941A1
(en)
|
2013-08-16 |
2015-02-19 |
Rana Therapeutics, Inc. |
Oligonucleotides targeting euchromatin regions of genes
|
|
CN112080502A
(zh)
*
|
2013-10-11 |
2020-12-15 |
Ionis制药公司 |
用于调节c9orf72表达的组合物
|
|
CN106062003A
(zh)
|
2013-11-12 |
2016-10-26 |
赛诺菲生物技术公司 |
用于与pcsk9抑制剂一起使用的给药方案
|
|
DK3087183T3
(da)
|
2013-12-24 |
2020-09-14 |
Ionis Pharmaceuticals Inc |
Modulation af angiopoietin-3-lignende ekspression
|
|
WO2015099122A1
(ja)
|
2013-12-26 |
2015-07-02 |
学校法人東京医科大学 |
遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途
|
|
RU2697094C2
(ru)
|
2013-12-27 |
2019-08-12 |
Бонак Корпорейшн |
ИСКУССТВЕННАЯ мкРНК С СООТВЕТСТВИЕМ ДЛЯ КОНТРОЛЯ ЭКСПРЕССИИ ГЕНОВ И ЕЕ ПРИМЕНЕНИЕ
|
|
JPWO2015108048A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
|
EP3095460A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
|
|
JPWO2015108047A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
|
PT3094728T
(pt)
|
2014-01-16 |
2022-05-19 |
Wave Life Sciences Ltd |
Desenho quiral
|
|
PT3137596T
(pt)
|
2014-05-01 |
2019-09-27 |
Ionis Pharmaceuticals Inc |
Composições e métodos para modulação da expressão do factor b do complemento
|
|
US9994855B2
(en)
|
2014-05-01 |
2018-06-12 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating growth hormone receptor expression
|
|
US9382540B2
(en)
|
2014-05-01 |
2016-07-05 |
Isis Pharmaceuticals, Inc |
Compositions and methods for modulating angiopoietin-like 3 expression
|
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
|
WO2015179693A1
(en)
|
2014-05-22 |
2015-11-26 |
Isis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
|
KR20240017117A
(ko)
|
2014-07-16 |
2024-02-06 |
사노피 바이오테크놀로지 |
이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
|
|
KR20170055474A
(ko)
*
|
2014-07-31 |
2017-05-19 |
아카데미아 시니카 |
길항 pd-1 압타머 및 암 요법 관련 적용에서의 그의 적용
|
|
WO2016024205A1
(en)
|
2014-08-15 |
2016-02-18 |
Pfizer Inc. |
Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
|
|
GB2547586A
(en)
*
|
2014-08-20 |
2017-08-23 |
Lifesplice Pharma Llc |
Splice modulating oligonucleotides and methods of use thereof(In the PCT request)
|
|
WO2016040589A1
(en)
|
2014-09-12 |
2016-03-17 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
|
US9657099B2
(en)
|
2014-09-16 |
2017-05-23 |
Regeneron Pharmaceuticals, Inc. |
Anti-glucagon antibodies
|
|
KR102620328B1
(ko)
|
2014-10-03 |
2024-01-02 |
콜드스프링하버러보러토리 |
핵 유전자 산출량의 표적화 증강
|
|
RU2017114156A
(ru)
|
2014-10-10 |
2018-11-15 |
Ф. Хоффманн-Ля Рош Аг |
N-ацетилгалактозаминовые (galnac) фосфорамитиды, их конъюгаты с нуклеиновыми кислотами и их применение
|
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
|
CA2966044A1
(en)
|
2014-10-30 |
2016-05-06 |
The General Hospital Corporation |
Methods for modulating atrx-dependent gene repression
|
|
EP3212794B1
(en)
|
2014-10-30 |
2021-04-07 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
|
US10266895B2
(en)
|
2014-11-05 |
2019-04-23 |
Hitachi Chemical Company Ltd. |
Exosomes and microvesicles in intestinal luminal fluids and stool and use of same for the assessment of inflammatory bowel disease
|
|
WO2016077537A1
(en)
|
2014-11-12 |
2016-05-19 |
Hitachi Chemical Co., Ltd. |
Method and device for diagnosing organ injury
|
|
WO2016077687A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
WO2016096938A1
(en)
|
2014-12-16 |
2016-06-23 |
Roche Innovation Center Copenhagen A/S |
Chiral toxicity screening method
|
|
CA2971827A1
(en)
|
2014-12-27 |
2016-06-30 |
Bonac Corporation |
Naturally occuring mirna for controlling gene expression, and use of same
|
|
EP3254104B1
(en)
|
2015-02-04 |
2021-08-25 |
Bristol-Myers Squibb Company |
Methods of selecting therapeutic molecules
|
|
RU2017127609A
(ru)
|
2015-02-04 |
2019-03-04 |
Ф. Хоффманн-Ля Рош Аг |
Антисмысловые олигомеры тау-белка и их применение
|
|
WO2016130943A1
(en)
|
2015-02-13 |
2016-08-18 |
Rana Therapeutics, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
US10900036B2
(en)
|
2015-03-17 |
2021-01-26 |
The General Hospital Corporation |
RNA interactome of polycomb repressive complex 1 (PRC1)
|
|
CA2981068C
(en)
|
2015-03-26 |
2021-12-14 |
Women & Infants Hospital Of Rhode Island |
Therapy for malignant disease comprising the inhibition of human epididymal secretory protein e4 and immune checkpoint inhibitors
|
|
CN108064289A
(zh)
|
2015-03-27 |
2018-05-22 |
株式会社博纳克 |
具有递送功能和基因表达调控能力的单链核酸分子
|
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
PL3283080T3
(pl)
|
2015-04-16 |
2020-07-27 |
Ionis Pharmaceuticals, Inc. |
Kompozycja do modulowania ekspresji c9orf72
|
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
|
EP3311165B1
(en)
|
2015-06-19 |
2020-12-09 |
University Of Rochester |
Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
|
|
CN109477106B
(zh)
|
2015-07-10 |
2022-10-04 |
Ionis制药公司 |
二酰基甘油酰基转移酶2(dgat2)的调节剂
|
|
MA43072A
(fr)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
|
EA201890519A1
(ru)
|
2015-08-18 |
2018-07-31 |
Ридженерон Фармасьютикалз, Инк. |
Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
|
|
WO2017040520A1
(en)
|
2015-08-31 |
2017-03-09 |
Hitachi Chemical Co., Ltd. |
Molecular methods for assessing urothelial disease
|
|
CN108135845B
(zh)
|
2015-09-18 |
2021-10-29 |
Dnarx公司 |
用于体内核酸表达的系统和方法
|
|
KR20220105174A
(ko)
|
2015-10-09 |
2022-07-26 |
유니버시티 오브 사우스앰톤 |
유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
|
|
US11021707B2
(en)
|
2015-10-19 |
2021-06-01 |
Phio Pharmaceuticals Corp. |
Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
|
|
EP3394258B1
(en)
|
2015-10-22 |
2021-09-22 |
Roche Innovation Center Copenhagen A/S |
In vitro toxicity screening assay
|
|
US11260073B2
(en)
|
2015-11-02 |
2022-03-01 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating C90RF72
|
|
KR20250078597A
(ko)
|
2015-11-06 |
2025-06-02 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포리포프로테인 (a) 발현 조정
|
|
CN108350431A
(zh)
|
2015-11-12 |
2018-07-31 |
豪夫迈·罗氏有限公司 |
用于确定候选药物的功效特征的方法
|
|
CN109312343B
(zh)
|
2015-12-14 |
2022-09-27 |
冷泉港实验室 |
用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体
|
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
|
EP3418289A4
(en)
|
2016-02-17 |
2019-10-30 |
Tokyo Institute of Technology |
ARTIFICIAL NUCLEOSIDE AND ARTIFICIAL NUCLEOTIDE AND ARTIFICIAL OLIGONUCLEOTIDE
|
|
US11364258B2
(en)
|
2016-03-04 |
2022-06-21 |
Rhode Island Hospital |
Methods for treating chondrosarcoma using microrna(miR)
|
|
PT3430141T
(pt)
|
2016-03-14 |
2021-02-25 |
Hoffmann La Roche |
Oligonucleótidos para redução da expressão de pd-l1
|
|
CN109153697A
(zh)
|
2016-04-14 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
三苯甲基-单-GalNAc化合物及其用途
|
|
SG11201809002RA
(en)
|
2016-04-29 |
2018-11-29 |
Univ Nanyang Tech |
G-quadruplex-containing antisense oligonucleotides
|
|
DK3455232T3
(da)
*
|
2016-05-12 |
2020-07-06 |
Roche Innovation Ct Copenhagen As |
Forbedret kobling af stereodefinerede oxazaphospholidin-phosphoramidit-monomerer til nukleosid eller oligonukleotid
|
|
MA45496A
(fr)
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
|
JP7012033B2
(ja)
|
2016-06-17 |
2022-02-10 |
エフ．ホフマン－ラ ロシュ アーゲー |
インビトロ腎毒性スクリーニングアッセイ
|
|
US11105794B2
(en)
|
2016-06-17 |
2021-08-31 |
Hoffmann-La Roche Inc. |
In vitro nephrotoxicity screening assay
|
|
WO2018062510A1
(ja)
|
2016-09-29 |
2018-04-05 |
国立大学法人東京医科歯科大学 |
オーバーハングを有する二本鎖核酸複合体
|
|
JOP20190065A1
(ar)
|
2016-09-29 |
2019-03-28 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن tau
|
|
US11400161B2
(en)
|
2016-10-06 |
2022-08-02 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
|
US20190248888A1
(en)
|
2016-10-20 |
2019-08-15 |
Regeneron Pharmaceuticals, Inc. |
Methods of lowering blood glucose levels
|
|
WO2018085656A1
(en)
*
|
2016-11-03 |
2018-05-11 |
Ohio State Innovation Foundation |
Antisense oligomers targeting hoxb-as3 long non-coding rna
|
|
JP2019535839A
(ja)
|
2016-11-29 |
2019-12-12 |
ピュアテック ヘルス エルエルシー |
治療剤の送達のためのエクソソーム
|
|
EP3568480A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb2 expression
|
|
US20200216845A1
(en)
|
2017-01-13 |
2020-07-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rela expression
|
|
WO2018130582A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rel expression
|
|
EP3568479A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb1 expression
|
|
EP3568481A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating relb expression
|
|
CA3052801A1
(en)
|
2017-02-06 |
2018-08-09 |
Nissan Chemical Corporation |
Single-stranded oligonucleotide
|
|
WO2018155450A1
(ja)
*
|
2017-02-21 |
2018-08-30 |
国立大学法人大阪大学 |
アンチセンスオリゴ核酸
|
|
WO2018165564A1
(en)
|
2017-03-09 |
2018-09-13 |
Ionis Pharmaceuticals, Inc. |
Morpholino modified oligomeric compounds
|
|
CN116392609A
(zh)
|
2017-03-23 |
2023-07-07 |
Dnarx公司 |
用于体内核酸表达的系统和方法
|
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
|
US11638717B2
(en)
|
2017-03-29 |
2023-05-02 |
Shionogi & Co., Ltd. |
Complex of nucleic acid medicine and multibranched lipid
|
|
NO344051B1
(en)
*
|
2017-05-04 |
2019-08-26 |
Patogen As |
Novel virus in Fish and Method for detection
|
|
EP3618839A4
(en)
|
2017-05-05 |
2021-06-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
EP3633036A4
(en)
*
|
2017-05-26 |
2021-03-17 |
National Cerebral and Cardiovascular Center |
NUCLEIC ACID TARGETING ANTI-SENSES PCSK9
|
|
JP6974872B2
(ja)
|
2017-06-30 |
2021-12-01 |
国立大学法人 東京医科歯科大学 |
ヘテロ二本鎖型ａｎｔｉｍｉＲ
|
|
AU2018307294B2
(en)
|
2017-07-26 |
2025-04-17 |
Nissan Chemical Corporation |
Single-stranded oligonucleotide
|
|
SMT202400071T1
(it)
|
2017-08-25 |
2024-03-13 |
Stoke Therapeutics Inc |
Oligomeri antisenso per il trattamento di condizioni e malattie
|
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
CN111479924B
(zh)
|
2017-10-16 |
2024-06-14 |
沃雅戈治疗公司 |
肌萎缩性侧索硬化症(als)的治疗
|
|
CR20210262A
(es)
|
2017-10-16 |
2022-06-27 |
Hoffmann La Roche |
MOLÉCULA DE ÁCIDOS NUCLEICOS PARA LA REDUCCIÓN DEL ARNm DE PAPD5 Y PAPD7 EN EL TRATAMIENTO DE LA INFECCIÓN DE LA HEPATITIS B (DIVISIONAL DEL EXPEDIENTE 2020-0205)
|
|
WO2019115416A2
(en)
|
2017-12-11 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating fndc3b expression
|
|
KR20200104339A
(ko)
|
2017-12-21 |
2020-09-03 |
에프. 호프만-라 로슈 아게 |
Htra1 rna 길항제에 대한 동반 진단제
|
|
WO2019122279A1
(en)
|
2017-12-22 |
2019-06-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
|
JP2021508327A
(ja)
|
2017-12-22 |
2021-03-04 |
ロシュ イノベーション センター コペンハーゲン エーエス |
新規のチオホスホラミダイト
|
|
CN111448317B
(zh)
|
2017-12-22 |
2025-07-04 |
罗氏创新中心哥本哈根有限公司 |
包含二硫代磷酸酯核苷间键的缺口聚物寡核苷酸
|
|
WO2019137883A1
(en)
|
2018-01-10 |
2019-07-18 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating pias4 expression
|
|
CN111556894A
(zh)
|
2018-01-12 |
2020-08-18 |
哥本哈根罗氏创新中心 |
用于调控gsk3b表达的寡核苷酸
|
|
SG11202006142PA
(en)
|
2018-01-12 |
2020-07-29 |
Roche Innovation Ct Copenhagen As |
Alpha-synuclein antisense oligonucleotides and uses thereof
|
|
US11447775B2
(en)
|
2018-01-12 |
2022-09-20 |
Bristol-Myers Squibb Company |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
|
CN111819283A
(zh)
|
2018-01-12 |
2020-10-23 |
百时美施贵宝公司 |
靶向α-突触核蛋白的反义寡核苷酸及其用途
|
|
CN111615558A
(zh)
|
2018-01-17 |
2020-09-01 |
罗氏创新中心哥本哈根有限公司 |
用于调节erc1表达的寡核苷酸
|
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
|
MX2020008581A
(es)
|
2018-02-21 |
2020-09-21 |
Bristol Myers Squibb Co |
Oligonucleotidos antisentido de la proteina cinasa del tipo ii delta dependiente del calcio/calmodulina (camk2d) y sus usos.
|
|
WO2019167995A1
(ja)
|
2018-02-28 |
2019-09-06 |
国立大学法人東京医科歯科大学 |
虚血病変部位特異的な遺伝子治療法
|
|
WO2019177061A1
(ja)
|
2018-03-14 |
2019-09-19 |
国立大学法人東京医科歯科大学 |
核酸複合体
|
|
WO2019181946A1
(ja)
|
2018-03-19 |
2019-09-26 |
国立大学法人東京医科歯科大学 |
毒性が軽減した核酸
|
|
AU2019237599A1
(en)
|
2018-03-20 |
2020-11-12 |
Nissan Chemical Corporation |
Antisense oligonucleotide having reduced toxicity
|
|
EP3770257A4
(en)
|
2018-03-22 |
2022-03-09 |
National University Corporation Tokyo Medical and Dental University |
BHS-PASSING LIPID LIGAND OF A HETERONUCLEIC ACID
|
|
CA3095134A1
(en)
|
2018-03-28 |
2019-10-03 |
Board Of Regents, The University Of Texas System |
Identification of epigenetic alterations in dna isolated from exosomes
|
|
RU2020135289A
(ru)
|
2018-04-05 |
2022-05-05 |
Ф. Хоффманн-Ля Рош Аг |
Применение ингибиторов fubp1 для лечения инфекции вирусом гепатита в
|
|
US12060558B2
(en)
|
2018-05-04 |
2024-08-13 |
Stoke Therapeutics, Inc. |
Methods and compositions for treatment of cholesteryl ester storage disease
|
|
CR20200605A
(es)
|
2018-05-09 |
2021-01-29 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para la reducción de la expresión de fxi
|
|
US11833168B2
(en)
*
|
2018-06-14 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing STMN2 expression
|
|
JP7565218B2
(ja)
|
2018-07-02 |
2024-10-10 |
ボイジャー セラピューティクス インコーポレイテッド |
筋萎縮性側索硬化症および脊髄に関連する障害の治療
|
|
SG11202012759XA
(en)
|
2018-07-03 |
2021-01-28 |
Hoffmann La Roche |
Oligonucleotides for modulating tau expression
|
|
KR20210033004A
(ko)
|
2018-07-13 |
2021-03-25 |
에프. 호프만-라 로슈 아게 |
Rtel1의 발현을 조절하기 위한 올리고뉴클레오티드
|
|
EP3831408A4
(en)
|
2018-07-27 |
2021-11-17 |
Osaka University |
COMPOSITION TO INHIBIT AGING, PREVENT, IMPROVE, OR TREAT AGE-RELATED DISEASES, OR EXTEND LIFE
|
|
KR20210041537A
(ko)
|
2018-07-31 |
2021-04-15 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
포스포로트리티오에이트 뉴클레오사이드간 연결을 포함하는 올리고뉴클레오타이드
|
|
EP4122943B1
(en)
|
2018-07-31 |
2024-05-29 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
EA202190416A1
(ru)
|
2018-08-02 |
2021-06-23 |
Дайн Терапьютикс, Инк. |
Мышечно-специфические комлексы и их применение для лечения плече-лопаточно-лицевой мышечной дистрофии
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
WO2020077390A1
(en)
*
|
2018-10-18 |
2020-04-23 |
Murdoch University |
Antisense therapy for ptp1b related conditions
|
|
WO2020169696A1
(en)
|
2019-02-20 |
2020-08-27 |
Roche Innovation Center Copenhagen A/S |
Novel phosphoramidites
|
|
MX2021009950A
(es)
|
2019-02-20 |
2021-09-21 |
Roche Innovation Ct Copenhagen As |
Oligonucleotidos gapmeros de fosfonoacetato.
|
|
WO2020184700A1
(ja)
|
2019-03-14 |
2020-09-17 |
レナセラピューティクス株式会社 |
Ｉｈｈ発現を調節するための核酸複合体
|
|
WO2020209285A1
(ja)
|
2019-04-08 |
2020-10-15 |
国立大学法人東京医科歯科大学 |
筋疾患治療用医薬組成物
|
|
EP4005602A4
(en)
|
2019-07-30 |
2024-06-12 |
Shionogi & Co., Ltd |
NUCLEIC ACID AGENT TARGETED AGAINST MURF1
|
|
US20250115904A1
(en)
|
2019-08-14 |
2025-04-10 |
Lonza Sales Ag |
Extracellular vesicle-aso constructs targeting stat6
|
|
JP2022544935A
(ja)
|
2019-08-14 |
2022-10-24 |
コディアック バイオサイエンシーズ， インコーポレイテッド |
細胞外小胞－ｎｌｒｐ３アンタゴニスト
|
|
WO2021030769A1
(en)
|
2019-08-14 |
2021-02-18 |
Codiak Biosciences, Inc. |
Extracellular vesicles with nras antisense oligonucleotides
|
|
EP4013872A1
(en)
|
2019-08-14 |
2022-06-22 |
Codiak BioSciences, Inc. |
Extracellular vesicles with antisense oligonucleotides targeting kras
|
|
US20230002764A1
(en)
|
2019-08-14 |
2023-01-05 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting cebp/beta
|
|
WO2021030778A1
(en)
|
2019-08-15 |
2021-02-18 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds and uses thereof
|
|
EP4019088A4
(en)
*
|
2019-08-23 |
2024-01-17 |
National University Corporation Tokai National Higher Education and Research System |
INHIBITOR OF RNA ACTION AND ITS USE
|
|
WO2021054370A1
(ja)
|
2019-09-18 |
2021-03-25 |
国立大学法人東京医科歯科大学 |
核酸複合体
|
|
EP4034247A1
(en)
|
2019-09-25 |
2022-08-03 |
Codiak BioSciences, Inc. |
Sting agonist comprising exosomes for treating neuroimmunological disorders
|
|
US20240117346A1
(en)
|
2019-10-11 |
2024-04-11 |
National University Corporation Tokyo Medical And Dental University |
Modified hetero nucleic acids
|
|
CA3163490A1
(en)
|
2019-12-24 |
2021-07-01 |
F. Hoffman-La Roche Ag |
Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
|
|
AU2020415322A1
(en)
|
2019-12-24 |
2022-06-16 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combination of antiviral agents targeting HBV and/or an immune modulator for treatment of HBV
|
|
CA3169474A1
(en)
|
2020-01-31 |
2021-08-05 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Antisense oligonucleotide of atn1
|
|
JPWO2021177418A1
(cg-RX-API-DMAC7.html)
|
2020-03-04 |
2021-09-10 |
|
|
|
WO2021184020A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Methods of treating neuroinflammation
|
|
WO2021184021A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting pmp22
|
|
JPWO2021187392A1
(cg-RX-API-DMAC7.html)
|
2020-03-16 |
2021-09-23 |
|
|
|
EP4121534A1
(en)
|
2020-03-18 |
2023-01-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
|
CA3173647A1
(en)
|
2020-05-11 |
2021-11-18 |
Isabel AZNAREZ |
Opa1 antisense oligomers for treatment of conditions and diseases
|
|
CN115968374A
(zh)
|
2020-06-15 |
2023-04-14 |
Liid制药股份有限公司 |
交联型核苷及核苷酸
|
|
WO2022076596A1
(en)
|
2020-10-06 |
2022-04-14 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting stat6
|
|
EP4228638A4
(en)
*
|
2020-10-16 |
2025-02-05 |
University Of Florida Research Foundation, Incorporated |
THERAPEUTIC USE OF GLUCOCORTICOIDS WITH ANABOLIC ACTION IN SKELETAL MUSCLE
|
|
US11987795B2
(en)
|
2020-11-24 |
2024-05-21 |
The Broad Institute, Inc. |
Methods of modulating SLC7A11 pre-mRNA transcripts for diseases and conditions associated with expression of SLC7A11
|
|
CR20230308A
(es)
|
2020-12-11 |
2023-09-08 |
Civi Biopharma Inc |
Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
|
|
WO2022136466A1
(en)
|
2020-12-23 |
2022-06-30 |
Argonaute RNA Limited |
Treatment of cardiovascular disease
|
|
IL304048A
(en)
|
2020-12-31 |
2023-08-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CN117157093A
(zh)
|
2021-02-17 |
2023-12-01 |
隆萨销售股份有限公司 |
细胞外囊泡-nlrp3拮抗剂
|
|
US20240209368A1
(en)
|
2021-04-01 |
2024-06-27 |
Lonza Sales Ag |
Extracellular vesicle compositions
|
|
EP4349986A4
(en)
|
2021-05-25 |
2025-11-19 |
Univ Nat Corp Tokyo Medical & Dental |
HETERONUCLEIC ACID WITH A CONTENT OF ?????? OR ????
|
|
EP4347828A1
(en)
|
2021-05-29 |
2024-04-10 |
1Globe Health Institute LLC |
Short duplex dna as a novel gene silencing technology and use thereof
|
|
CN117858946A
(zh)
|
2021-05-29 |
2024-04-09 |
强新科技国际研究院 |
作为新型基因沉默技术的非对称短双链体dna及其应用
|
|
CN117412773A
(zh)
|
2021-05-31 |
2024-01-16 |
瑞纳治疗公司 |
配体结合核酸复合物
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
TW202333748A
(zh)
|
2021-07-19 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
用於處置具有或有風險發展非原發性高草酸鹽尿疾病或病症的個體的方法及組成物
|
|
US20240352468A1
(en)
|
2021-08-04 |
2024-10-24 |
The University Of Tokyo |
Hairpin nucleic acid composition
|
|
JPWO2023022229A1
(cg-RX-API-DMAC7.html)
|
2021-08-19 |
2023-02-23 |
|
|
|
EP4389893A4
(en)
|
2021-08-21 |
2025-09-10 |
Takeda Pharmaceuticals Co |
PEPTIDE-DRUG CONJUGATE BINDING HUMAN TRANSFERRIN RECEPTOR
|
|
JP2024532476A
(ja)
*
|
2021-09-02 |
2024-09-05 |
モレキュラー アクシオム エルエルシー |
Ｎｌｒｐ３またはｎｌｒｐ１発現を調節するための組成物及び方法
|
|
EP4402263A2
(en)
|
2021-09-14 |
2024-07-24 |
Argonaute Rna Limited |
Treatment of cardiovascular disease
|
|
US20250179486A1
(en)
|
2021-09-15 |
2025-06-05 |
National University Corporation Tokyo Medical And Dental University |
Heteronucleic acid including 2'-modified nucleoside
|
|
AU2022345881A1
(en)
|
2021-09-20 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
|
JPWO2023080159A1
(cg-RX-API-DMAC7.html)
|
2021-11-02 |
2023-05-11 |
|
|
|
CA3234478A1
(en)
|
2021-11-11 |
2023-05-19 |
Souphalone LUANGSAY |
Pharmaceutical combinations for treatment of hbv
|
|
DE102021131135A1
(de)
|
2021-11-26 |
2023-06-01 |
Zf Cv Systems Global Gmbh |
Funkkommunikationsmodul und Verfahren zum Absetzen eines Notrufs per Funkkommunikation
|
|
EP4448106A1
(en)
|
2021-12-17 |
2024-10-23 |
Hoffmann-La Roche Inc. |
Combination of oligonucleotides for modulating rtel1 and fubp1
|
|
IL315546A
(en)
|
2022-03-16 |
2024-11-01 |
Empirico Inc |
GALNAC compositions to improve siRNA bioavailability
|
|
JP2025512835A
(ja)
|
2022-03-28 |
2025-04-22 |
エンピリコ インク． |
修飾オリゴヌクレオチド
|
|
CN119183457A
(zh)
|
2022-04-15 |
2024-12-24 |
达因疗法公司 |
用于治疗强直性肌营养不良的肌肉靶向复合物和制剂
|
|
EP4561636A1
(en)
|
2022-07-29 |
2025-06-04 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
|
EP4581143A1
(en)
|
2022-08-29 |
2025-07-09 |
University of Rochester |
Antisense oligonucleotide-based anti-fibrotic therapeutics
|
|
EP4340411A1
(en)
|
2022-09-19 |
2024-03-20 |
Cellnex Italia S.p.A |
System for monitoring the operating state of the emergency call service into tunnels
|
|
WO2024071099A1
(ja)
|
2022-09-29 |
2024-04-04 |
国立大学法人東京医科歯科大学 |
５'－シクロプロピレン修飾を含む核酸分子
|
|
WO2024098061A2
(en)
|
2022-11-04 |
2024-05-10 |
Genkardia Inc. |
Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
|
|
US20240182561A1
(en)
|
2022-11-04 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
EP4619438A2
(en)
|
2022-11-14 |
2025-09-24 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
WO2024175588A1
(en)
|
2023-02-21 |
2024-08-29 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
|
EP4669750A2
(en)
|
2023-02-21 |
2025-12-31 |
Vib Vzw |
SYNAPTOGYRIN-3 EXPRESSION INHIBITORS
|
|
WO2024226761A2
(en)
|
2023-04-26 |
2024-10-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for treating amyotrophic lateral sclerosis
|